^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Miripla (miriplatin)

i
Other names: SM-11355, SM 11355, DACHPM , SMP-11355
Associations
Trials
Company:
Sumitomo Pharma
Drug class:
DNA synthesis inhibitor, DNA cross linking agent
Related drugs:
Associations
Trials
2ms
Mitophagy and Bip-PERK-eIF2α-ATF4 Axis-Mediated ER Stress Mediate Miriplatin-Loaded Liposome's Anti-Colorectal Cancer Action. (PubMed, Cell Prolif)
LMPt enters the cell mainly through caveolin-mediated endocytosis, and then fuses with endosomes and lysosomes to deliver MPt to mitochondria and the endoplasmic reticulum to induce mitophagy based on the fusion of lysosomes and mitochondria, and endoplasmic reticulum stress and subsequent apoptosis via the Bip-PERK-eIF2α-ATF4 axis to exert an anti-breast cancer effect.
Journal
|
ATF4 (Activating Transcription Factor 4)
|
Miripla (miriplatin)
almost2years
Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment. (PubMed, J Control Release)
FOLFOX regimen, composed of folinic acid, 5-fluorouracil (5-FU) and oxaliplatin (OXP), has been used as clinical standard therapeutic regimen in treatments of colorectal cancer (CRC) and esophageal squamous cell carcinoma (ESCC)...Herein, a lipid core-shell nanoparticle codelivery platform was designed for simultaneous encapsulation of variant FOLFOX composed of miriplatin (MiPt), 5-Fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP), calcium folinate (CF) and PD-L1 siRNA (siPD-L1) with high efficiencies, and their synergistic anti-tumor mechanisms were studied, respectively...CF worked as the sensitizer of FdUMP. The enhanced long-term anti-tumor effect of the prepared "all-in-one" formulation compared to free drug regimen and other controls, was verified in heterotopic CRC mice models and ESCC mice models, providing new thoughts for researchers and showing a promising prospect of translation into clinical applications.
Journal
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
|
5-fluorouracil • oxaliplatin • leucovorin calcium • Miripla (miriplatin)
2years
Miriplatin-loaded liposome, as a novel mitophagy inducer, suppresses pancreatic cancer proliferation through blocking POLG and TFAM-mediated mtDNA replication. (PubMed, Acta Pharm Sin B)
Both in gemcitabine (GEM)-resistant/sensitive (GEM-R/S) pancreatic cancer cells, LMPt exhibits prominent anti-cancer activity, led by faster cellular entry-induced larger accumulation of MPt. Self-assembly offers LMPt special efficacy and mechanisms. Prominent action and characteristic mechanism make LMPt a promising cancer candidate.
Journal
|
CAV1 (Caveolin 1) • TFAM (Transcription Factor A, Mitochondrial)
|
gemcitabine • Miripla (miriplatin)
over2years
Enhanced binding of β-catenin and β-TrCP mediates LMPt's anti-CSCs activity in colorectal cancer. (PubMed, Biochem Pharmacol)
Here, we report a liposome loaded with low toxicity and high effectiveness of miriplatin, lipo-miriplatin (LMPt) with high miriplatin loading, and robust stability, exhibiting a superior inhibitory effect on CSCs and non-CSCs. LMPt predominantly inhibits the survival of oxaliplatin-resistant (OXA-resistant) cells composed of CSCs...Further studies revealed that the strengthened binding of β-catenin and β-TrCP initiates ubiquitination and degradation of β-catenin induced by LMPt. In addition,the Apctransgenicmouse model, in which colon tumors are spontaneously formed, demonstrates LMPt's potent anti-non-CSCs activity in vivo.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • POU5F1 (POU Class 5 Homeobox 1) • NANOG (Nanog Homeobox)
|
oxaliplatin • Miripla (miriplatin)
over5years
Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma. (PubMed, J Gastroenterol)
Miriplatin plus irradiation had synergistic anti-tumor activity on HCC cells through PUMA-mediated apoptosis and cell cycle arrest. This combination may possibly be effective in treating locally advanced HCC.
Journal • PARP Biomarker
|
TP53 (Tumor protein P53)
|
TP53 expression
|
Miripla (miriplatin)